CurrentUnitedHealthcarePolicy 2026T0051DD

Chelation Therapy for Heavy Metal Toxicity and Overload Conditions

This UnitedHealthcare policy governs coverage of chelation therapy for Commercial and Individual Exchange benefit plans, specifying medically necessary indications (heavy metal overload) and not medically necessary uses (non-overload conditions and dental amalgam-related mercury).

Policy Summary

PayerUnitedHealthcare

PolicyChelation Therapy for Heavy Metal Toxicity and Overload Conditions

Policy CodePolicy 2026T0051DD

Change TypeNo material change

Effective DateJan 1, 2026

Next Review Date

Key ActionObtain prior authorization and document validated diagnostic testing confirming metal intoxication or iron overload before requesting chelation therapy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6example J-codes listed

5+heavy metals named

3major evidence sources cited

959participants in 2024 EDTA trial

1708participants in TACT trial

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

listedFDA high-risk groups

Coverage Criteria for Chelation Therapy

Medically necessary indications (Heavy metal overload)

Covered when ALL of the following are met:

Heavy metal overload indication: There is an accurate diagnosis of heavy metal toxicity or overload (for example iron, copper, lead, aluminum).diagnosis demonstrated by appropriate testing and clinical evaluation

Chelation therapy is established and medically necessary for these overload conditions.

Not medically necessary / Unproven uses

Not covered (unproven) when ANY of the following apply:

Non-overload chronic/progressive disease: Chelation therapy used to treat chronic, progressive diseases associated with non-overload conditions (e.g., cardiovascular disease, rheumatoid arthritis, cancer, diabetes) where heavy metal overload has not been demonstrated.no demonstrated overload

Listed explicitly as unproven and not medically necessary.

Dental amalgam mercury claims: Chelation therapy used to treat purported mercury 'toxicity' from dental amalgam fillings when harm from amalgams has not been demonstrated except rare allergy cases.dental amalgam without documented toxicity

Explicitly listed as unproven and not medically necessary.

Coverage stance by indication

Policy stance by indication (summarized from evidence in document):

Iron overload (transfusional) - pediatric transfusion‑dependent hemoglobinopathies: Use of oral iron chelators (e.g., deferiprone [DFP], deferasirox [DFX]) is supported by randomized trial evidence demonstrating noninferiority of DFP versus DFX over 12 months in transfusion‑dependent hemoglobinopathies; monitoring includes serum ferritin and cardiac MRI T2*.per trial criteria (serum ferritin, cardiac MRI T2*)

DFP vs DFX noninferiority established in a phase 3 trial (Maggio et al. 2020).

EDTA chelation for cardiovascular disease (post‑MI with diabetes): Large randomized trials (TACT and the 2024 multicenter EDTA trial) did not show consistent reductions in composite cardiovascular endpoints in overall post‑MI populations; subgroup signals (for example participants with diabetes) are hypothesis‑generating but insufficient to support routine coverage for CVD prevention or treatment.no demonstrated reduction in composite primary endpoints in overall populations

2024 EDTA trial reduced blood lead levels but did not reduce CVD events; subgroup/post‑hoc analyses require replication.

Indications considered medically necessary

Covered when ALL of the following are met

Primary indications: Documented metal intoxication or iron overload confirmed by validated testing in appropriate biological samples; indication aligned with FDA‑approved uses and recognized drug compendia.validated test results present

Professional societies recommend chelation only for documented intoxication; FDA approves chelators for metal poisoning and iron overload and use should align with product labeling.

Non‑indicated / discouraged uses

Not covered / Not recommended for the following indications

Non‑overload and investigational uses: Use of chelation therapy for autism, cardiovascular disease prevention or treatment, neurodegenerative conditions (e.g., Alzheimer's, Parkinson's), stable ischemic heart disease, or to improve angina/exercise tolerance is not recommended or considered not medically necessary.n/a

Multiple specialty societies and guideline statements advise against these uses and evidence does not support clinical benefit.

Chelation therapy for chronic, progressive non‑overload diseases and for purported mercury ‘‘toxicity’’ from dental amalgam fillings is considered unproven and not medically necessary. The policy recognizes chelation as an established treatment only when there is an accurate diagnosis of metal overload; proposals to use chelation for chronic non‑overload conditions or to treat mercury exposure from dental amalgams lack high‑quality evidence of clinical benefit and therefore are not covered.

Multiple sections of the clinical evidence and policy synthesis state that dental amalgam restorations have not been shown to cause clinical harm in the general population (except rare allergy), and chelation to treat alleged amalgam‑related mercury exposure is not supported by the literature. Requests based solely on dental amalgam exposure without validated diagnostic evidence of mercury intoxication are not considered medically necessary.

Chelation therapy for chronic, progressive non‑overload conditions—such as cardiovascular disease, atherosclerosis, diabetes, cancer, Alzheimer’s disease, autism spectrum disorder, and Parkinson’s disease—is not supported by well‑designed peer‑reviewed studies and is considered unproven and not medically necessary. The policy explicitly lists these and many other non‑overload indications as uses for which chelation should not be submitted as a treatment option in the absence of documented metal overload.

The U.S. Food and Drug Administration has warned companies that made improper claims that chelating agents treat or cure autism. FDA‑approved chelators are indicated for specific toxicities such as lead poisoning and iron overload and are not approved to treat autism or autism‑related symptoms; claims to the contrary have prompted regulatory warnings and should not be relied upon as a basis for coverage.

Repeated here for clarity: chelation to treat alleged mercury ‘‘toxicity’’ from dental amalgam fillings is unproven. High‑quality evidence has not demonstrated clinically significant harm from dental amalgams in the general population, and chelation for amalgam‑related mercury exposure is not considered medically necessary except in rare, documented cases such as confirmed allergy or validated mercury intoxication supported by appropriate testing.

Routine use of intravenous EDTA chelation to improve clinical outcomes in people with atherosclerotic cardiovascular disease or in post‑procedure/post‑MI settings is not supported by consistent high‑quality evidence and therefore is not recommended for routine coverage. Large randomized trials and systematic reviews show no reliable reduction in major cardiovascular events in unselected populations; subgroup findings are hypothesis‑generating but insufficient to justify routine EDTA use for ASCVD.

Chelation therapy is considered medically appropriate only for documented metal intoxication or iron overload confirmed by validated testing in appropriate biological samples. Professional toxicology and medical societies advise that chelation should be reserved for diagnoses supported by validated laboratory or imaging evidence (for example, serum ferritin and cardiac MRI T2* for iron overload) and aligned with FDA‑approved indications; use outside those settings is discouraged and may be denied.

Provider Actions, Authorization, and Documentation

Example HCPCS/J codesHCPCS

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1,000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg.
J8499	Prescription drug, oral, nonchemotherapeutic, NOS

Procedure and infusion codesmixed

M0300	IV chelation therapy (chemical endarterectomy).
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Prior Authorization

Prior authorization may be required for chelation-related codes

Prior authorization is implied for chelation services and the listed injectable and infusion procedure/drug codes; benefit coverage is determined by the member-specific plan.

Example HCPCS/J codes listed: J0470, J0600, J0895, J3490, J3520, J8499.
Procedure/infusion codes listed: M0300, S9355.
Inclusion of a code in the policy does not guarantee coverage or payment — check the member's benefit plan.

Prior Authorization

Prior authorization: evidence and monitoring requirements

Requests for high-resource chelation regimens should include evidence of the trial diagnosis and relevant monitoring data to support medical necessity.

Provide diagnosis consistent with trial populations (e.g., transfusion-dependent hemoglobinopathy with iron overload).

Coding and Billing for Chelation Therapy

Example HCPCS/J codesHCPCS

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1,000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg.
J8499	Prescription drug, oral, nonchemotherapeutic, NOS

Procedure and infusion codesmixed

M0300	IV chelation therapy (chemical endarterectomy).
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Billing Rule

Prior authorization may be required for chelation-related codes (billing)

Prior authorization is implied for chelation therapy services and the listed injectable and infusion procedure/drug codes; verify authorization requirements prior to billing.

Codes provided for reference: J0470, J0600, J0895, J3490, J3520, J8499, M0300, S9355.
Inclusion of codes in the policy does not imply coverage — check member-specific benefits before submitting claims.

Background on Chelation Therapy and Evidence

Chelation therapy refers to administration of agents that bind metal ions (for example, EDTA, deferiprone, deferasirox or dimercaptosuccinic acid) to facilitate elimination of excess metals from the body. The choice of agent, route, and regimen depends on the specific metal and clinical context: for instance, EDTA (edetate disodium) is an intravenous chelator studied in cardiovascular trials, while oral chelators such as deferiprone and deferasirox are used for iron overload. Chelation is an established therapy for accurately diagnosed heavy metal intoxication or iron overload, but its use for proposed non‑overload indications is unsupported by current evidence.

Key Definitions

inv-27: Heavy metal overload — definition and diagnostic context

DefinitionA condition in which elevated body burden of metals (such as iron, copper, lead, aluminum, and mercury) has been accurately diagnosed by appropriate testing and clinical evaluation, potentially warranting chelation therapy.

Diagnostic contextRequires individualized history, appropriate choice of testing methods, and use of accurate and specific reference values to demonstrate overload before chelation is considered.

Typical toxinsExamples explicitly named include iron, copper, lead, aluminum, and mercury.

Treatment rationaleChelation is an established treatment to remove metal toxins by administering molecules that bind specific metals to facilitate excretion; agent, route, and regimen depend on the toxin and clinical context.

inv-28: Non-overload condition — definition

Definition

Policy Summary

PayerUnitedHealthcare

PolicyChelation Therapy for Heavy Metal Toxicity and Overload Conditions

Policy CodePolicy 2026T0051DD

Change TypeNo material change

Effective DateJan 1, 2026

Next Review Date

Key ActionObtain prior authorization and document validated diagnostic testing confirming metal intoxication or iron overload before requesting chelation therapy.

SourceLink

On This Page

Non‑overload conditions (Alzheimer's disease, autism, Parkinson's, many others): Evidence is insufficient, conflicting, or of low quality to support chelation therapy for non‑overload indications such as Alzheimer's disease, autism spectrum disorder, Parkinson's disease, and other listed conditions; systematic reviews and RCTs show no clear clinical benefit.lack of high‑quality RCT evidence demonstrating clinical benefit

Cochrane and other systematic reviews conclude insufficient evidence; small trials may show biomarker changes but not clinical efficacy.

Mercury from dental amalgam: High‑quality RCTs and systematic reviews do not support clinical harm from dental amalgam restorations nor the need for chelation therapy for amalgam‑related mercury exposure.no evidence of adverse clinical outcomes attributable to dental amalgam requiring chelation

Population studies attribute small proportions of blood mercury to amalgams; no causal evidence for fetal harm.

Include monitoring results such as serum ferritin and cardiac MRI T2*, and organ function data when applicable.

For repeated EDTA infusions, document trial protocol alignment and safety monitoring.

Prior Authorization

Align indication with FDA‑approved uses

Prior authorization should confirm the requested chelation indication aligns with FDA‑approved uses and recognized drug compendia; uses claiming treatment or cure for autism or other non‑approved indications should be excluded.

FDA‑approved indications include treatment of metal poisoning and iron overload only.
Reference a recognized drug compendium (e.g., AHFS or DrugDex) to verify agent‑specific approvals.

Note

Step therapy — informational

No explicit step therapy sequencing is mandated by the policy; comparative trials between oral chelators are summarized but do not require prior agent trials.

Selection between oral agents may consider randomized trial evidence, but the policy does not impose mandatory steps.
Review trial evidence for efficacy and safety when choosing among FDA‑approved oral chelators.

Step Therapy

Agent selection for iron chelation

When multiple FDA‑approved oral iron chelators are options, agent selection may be informed by randomized trial evidence comparing those agents and by documented intolerance or contraindication to alternatives.

Cite phase 3 noninferiority trials (e.g., DFP vs DFX) when justifying choice of oral chelator.
Document clinical reasons for preferring one approved agent over another (intolerance, adherence, organ function).

Step Therapy

Step requirements for chelation

Authorization of FDA‑approved chelating agents requires documentation of diagnosed metal poisoning or iron overload and evidence that standard-of-care management has been attempted when applicable.

Provide validated diagnostic test results confirming intoxication or overload.
Document prior standard-of-care measures and reasons for initiating chelation (e.g., failed/insufficient response, intolerance).

Documentation Required

Required diagnostic documentation

Diagnostic workup submitted for authorization must include the individual's history, the specific testing methods used, and accurate reference values demonstrating heavy metal overload.

Document relevant exposure and clinical history that support testing interpretation.
Specify the laboratory/method used and the reference ranges applied for the reported result.

Documentation Required

Diagnostic testing documentation for heavy metal intoxication

For heavy metal intoxication, provide validated diagnostic testing performed on appropriate biological samples; AAFP guidance supports chelation only when intoxication is confirmed by such testing.

Include test type, specimen source, and validated result values that confirm intoxication.
Reference AAFP position when documenting appropriateness for chelation.

Documentation Required

Required diagnostic documentation: validated test results

Authorization documentation must include validated test results from appropriate biological samples that confirm metal intoxication when chelation is proposed.

Attach laboratory or imaging reports (e.g., blood/urine metal levels, cardiac MRI T2* for iron overload) with reference ranges.
Ensure tests cited are those recognized by toxicology/medical specialty guidance.

Denial Risk

Denial triggers for non-overload indications

Requests to use chelation therapy for non‑overload chronic progressive diseases or to treat purported mercury 'toxicity' from dental amalgam fillings are considered unproven and may be denied.

Do not submit chelation for chronic non‑overload conditions without validated evidence of metal intoxication.
Claims of dental amalgam 'toxicity' as an indication for chelation are listed as unproven and not medically necessary.

Denial Risk

Non‑overload indications at risk for denial

Use of chelation therapy for non‑overload chronic progressive diseases such as cardiovascular disease, diabetes, Alzheimer’s, autism, and Parkinson’s is not supported by quality evidence and is at risk for denial.

Examples flagged for denial: cardiovascular disease, atherosclerosis, diabetes, cancer, Alzheimer’s disease, autism spectrum disorder, Parkinson’s disease.
Policy states insufficient evidence that chelation therapy is safe and effective for these conditions.

Denial Risk

Denial risk for non-indicated chelation

Chelation requests for indications other than documented metal intoxication or iron overload (i.e., conditions without validated diagnostic confirmation) are at risk of denial because major toxicology and medical organizations do not recommend chelation outside confirmed intoxication.

Ensure submitted cases include validated testing and appropriate biologic sample results to avoid denial.
Be aware major organizations warn against inappropriate chelation due to potential serious harms.

Clinical situations where acute or chronic heavy metal toxicity has not been demonstrated and chelation is hypothesized to reduce oxidative damage but lacks proven clinical efficacy.

ExamplesNon‑overload uses investigated include cardiovascular disease, rheumatoid arthritis, cancer, diabetes, neurodegenerative disorders, and claims related to dental amalgam mercury exposure.

Evidence stanceMechanism remains incompletely understood and high‑quality trials do not demonstrate consistent clinical benefit for these non‑overload indications.

inv-29: EDTA (edetate disodium) — definition and trial mentions

DefinitionEDTA (edetate disodium) is an intravenous chelating agent used to bind divalent metals (e.g., lead) and has been evaluated in large clinical trials of EDTA‑based infusion regimens.

Key trial mentionsA 2024 double‑masked, placebo‑controlled, multicenter trial randomized post‑MI patients with diabetes to 40 weekly EDTA‑based infusions or placebo (Lamas et al., 2024).

Clinical noteEDTA reduced blood lead levels in the 2024 trial but did not reduce overall cardiovascular event rates in the overall study population.

inv-30: DFP (deferiprone) — definition and trial context

DefinitionDFP (deferiprone) is an oral iron chelator used to treat transfusional iron overload and studied in randomized trials against other oral chelators.

Trial contextA phase 3 multicenter, randomized, open‑label noninferiority trial (Maggio et al., 2020) compared DFP with deferasirox (DFX) in pediatric transfusion‑dependent hemoglobinopathies (n=435) and demonstrated noninferiority for the primary composite efficacy endpoint over 12 months.

MonitoringEfficacy and safety monitoring in iron‑overloaded patients include serum ferritin and cardiac MRI T2* assessment per trial criteria.

inv-31: DMSA (dimercaptosuccinic acid) — definition and pediatric autism trial mention

DefinitionDMSA (dimercaptosuccinic acid) is an oral chelating agent evaluated in trials assessing heavy metal excretion and proposed uses such as autism spectrum disorder.

Pediatric autism trialA multi‑phase study assessed oral DMSA in children with ASD who were high excreters of heavy metals; overall, the Cochrane review found no evidence that multiple rounds of oral DMSA improved ASD symptoms and noted serious adverse events reported in prior reports.

Safety concernsPrior reports have described serious adverse events with DMSA use (hypocalcemia, renal impairment, and reported death), leading reviewers to conclude risks currently outweigh unproven benefits for ASD.

inv-32: Chelation therapy — general definition and approved uses

DefinitionChelation therapy is the administration of agents that bind metal ions (e.g., EDTA, deferiprone, deferasirox, DMSA) to facilitate removal of excess metals from the body.

Approved usesFDA‑approved indications for chelating agents include treatment of specific metal poisonings and iron overload; use should align with FDA labeling and recognized drug compendia.

Clinical considerationsAgent, route, regimen, and monitoring vary by toxin and indication; monitoring may include laboratory measures (e.g., ferritin), imaging (e.g., cardiac MRI T2*), and organ function assessments.

inv-33: Dental amalgam (DA) exposure — definition and notes on mercury contribution to blood levels

DefinitionDental amalgam (DA) exposure denotes the presence of mercury‑containing dental fillings, which can contribute to total blood mercury (TBHg) levels.

Magnitude of contributionIn a study of 4,484 pregnant women, DA fillings accounted for at least 6.47% of TBHg variability; seafood accounted for ~8.75% in the same population.

Clinical implicationHigh‑quality evidence to date does not show that DA‑related mercury causes adverse fetal outcomes; FDA guidance recommends certain high‑risk groups avoid DA when possible.